Efficacy of Matrifen in Patients Older Than 18 Years With Severe, Chronic Pain

NCT00556270 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2012-05-07

No results posted yet for this study

Summary

The aim of the study is to evaluate the efficacy and safety of matrifen in patients with severe and chronic pain who can only be sufficiently treated with opioid analgesics (WHO class 3).

Conditions

  • Severe, Chronic Pain

Interventions

DRUG

Matrifen

as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)

Sponsors & Collaborators

  • Nycomed

    lead INDUSTRY

Principal Investigators

  • Dr. Thomas D. Bethke, PhD, MD · Nycomed Deutschland GmbH, 78467 Konstanz, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Completion
2008-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00556270 on ClinicalTrials.gov